orexin

Abstract Post-viral syndromes are heterogeneous multisystem diseases without a uniform etiology that occur as a result of acute viral infections. During the COVID-19 pandemic, the number of patients increased dramatically due to infections with severe acute respiratory syndrome coronavirus 2...

Narcolepsy type 1 (NT1) is presumed to be an autoimmune disorder caused by hypothalamic loss of hypocretin (Hcrt; orexin). In postmortem NT1 brains, we observed an 11‐fold increase of CD4 + T‐cells in the Hcrt region compared with control hypothalami, without a corresponding rise in CD8 +...

This is the preprint. Go to post #9 for the published paper Disruption of the hypothalamic orexin system links SARS-CoV-2 infection to persistent cortical neuronal pathology Long COVID frequently presents with persistent neurological symptoms, including cognitive impairment, fatigue, and...

Significance This study establishes how narcolepsy type 1 (NT1) affects brain fluid dynamics through lack of orexins by comparing NT1 patients to healthy wake and sleeping controls. Using fast functional MRI, we revealed that even during wakefulness, NT1 leads to high vasomotor and low brain...

An integrative review on the orexin system and hypothalamic dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome: implications for precision medicine Noé López-Amador [Line breaks added] Abstract Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a debilitating...

The Orexin System and Its Impact on the Autonomic Nervous and Cardiometabolic System in Post-Acute Sequelae of COVID-19 Jana Ruhrländer, Styliani Syntila, Elisabeth Schieffer, Bernhard Schieffe [Line break added] Abstract Orexins (OXs) are critical for regulating circadian rhythms, arousal...

One of my doctors informed me today that this drug has been recently approved by NICE and is going to try me on it for my sleep issues. He said it will help when I feel too wired to get to sleep. Other insomnia sufferers might want to consider speaking to their doctor about it.

This is a press release from a small Swiss pharmaceutical company. I'm sharing it because the newly appointed chief scientific officer said: "Our lead product candidate, Quilience®, is an exciting technology that we discovered has partial orexin-2 binding activity, and therefore, offers...

Full title: Multiple Sclerosis: Melatonin, Orexin, and Ceramide Interact with Platelet Activation Coagulation Factors and Gut-Microbiome-Derived Butyrate in the Circadian Dysregulation of Mitochondria in Glia and Immune Cells Open access, https://www.mdpi.com/1422-0067/20/21/5500/htm

Open access at https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-019-1502-8